SMSunil Kashinath Mahajan

Sunil Kashinath Mahajan

*This is an algorithmically generated author record based on publicly available information.

Sunil Kashinath Mahajan has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Oncolytic viruses in cancer therapy: Mechanisms, challenges, and emerging clinical applications

    by Shivraj Popat Jadhav, Chandrashekhar Dinkar Patil, Ashish Yashwantrao Pawar, Deepak Devidas Sonawane, Sunil Kashinath Mahajan

  • Open Access

    GLP-1 Receptor Agonists: Advances in Mechanism, Therapeutic Applications, and Future Perspectives

    by Megha Pawar, Chandrashekhar Patil, Zubershaha Fakir, Durgesh Pagar, Sunil Mahajan

    Worldwide prevalence of type 2 diabetes mellitus (T2DM) and obesity has heightened the need to find treatments that control hyperglycemia, together with weight gain and resultant organ damage. Under this arrangement, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as transformative agents. They act through both intra- and extrapancreatic pathways to promote glucose-dependent insulin secretion, lower glucagon concentrations, slow stomach emptying, and control circuits of cerebral appetite. This helps the body regulate blood glucose levels, leading to clinically significant weight loss. In addition to regulating metabolism, strong cardiovascular and renal outcome trial data (including STEP, SELECT, and FLOW) suggest that they can lower the disease burden of serious cardiovascular events and protect kidney functioning. It means they are disease-modifying agents. Other barriers include their high cost, gastrointestinal side effects, injectable formulations, and lack of long-term safety information, although they are an effective intervention for achieving greater use. Recently, novel agents such as oral semaglutide, dual and triple incretin agonists (tirzepatide, retatrutide), and drug-based combinations with sodium-glucose cotransporter-2 (SGLT2) have revolutionized the treatment of the disease and improved its clinical utility. Individualized optimization of treatment using precision medicine, in the form of tailored behavior, with respect to phenotypes and comorbidities, holds promise to enhance outcomes. The combination of glycemic control, long-term weight loss, and organ protection is shifting the approach to cardiac, renal, and other organ health, leveraging the action of GLP-1 receptor agonists.

  • Open Access

    Computational Drug Design and Development: Artificial Intelligence, Molecular Modeling, and Structure-Based Discovery

    by Khemchand R. Surana, Gaurav N. Kasar, Sunil K. Mahajan

    For us editors, writing “Computational Drug Design and Development: Artificial Intelligence, Molecular Modeling, and Structure-Based Discovery” has been an interesting and educational experience. We have seen the quick development of computational tools in the pharmaceutical sciences over time. What was formerly thought of as a specialized method is now a crucial component of research and drug development. We have attempted to convey these developments in a way that is understandable, useful, and significant for scholars, professionals, and students in this book. The groundwork is laid in the first chapter, Novel Techniques of Drug Design and Development, which outlines the fundamentals of contemporary computational drug design. It makes a distinction between structure-based and ligand-based methods and considers how machine learning and artificial intelligence are progressively shortening development times while increasing forecast accuracy. Pharmacophores are covered in detail in the second chapter, Pharmacophore-Based Drug Design and Drug Delivery. The chapter describes how software tools such as MOE and LigandScout help find important chemical interactions and direct drug delivery tactics, as well as how three-dimensional pharmacophore models are constructed. Drug Metabolism and Pharmacokinetics (DMPK) Profiling is the main subject of Chapter 3. Here, we have highlighted the importance of in-silico ADME prediction using tools like Simcyp and GastroPlus, particularly in safety and regulatory assessments. The focus of the fourth chapter, Drug Design Approaches for Biotechnology, is on biologics, including proteins, peptides, and monoclonal antibodies. This chapter discusses how computational techniques are being applied to solve problems with stability, delivery, and immune response in the design of biologics. The use of QSAR models to improve predictive reliability is presented in chapter five, The Concept of Pharmacophore Mapping, along with techniques for virtual screening, hit detection, and lead optimization. An overview of popular computational programs, such as AutoDock, GOLD, GROMACS, AMBER, SwissADME, and pkCSM, is given in Chapter 6. Since these are particularly helpful for academic and laboratory learning, we have also included widely used open-source software. Toxicity Prediction by Computational Software is covered in Chapter 7. Early prediction using tools like VEGA QSAR, TOPKAT, and Derek Nexus can greatly lower risks throughout development because toxicity is still a key reason of drug withdrawal. We hope that the case studies, comparison tables, and workflow diagrams in the final section will aid in practical comprehension. We also provide a brief overview of how artificial intelligence will influence drug creation in the future. We sincerely hope that this book proves helpful to its readers. If it encourages curiosity or sparks new research ideas, we will consider our effort worthwhile.

  • Open Access

    Development and Validation of a Robust RP-HPLC Method for the Estimation of Remogliflozin Etabonate in Bulk and Tablet Dosage Forms

    by Kiran Prakash Surywanshi, Shivraj Popat Jadhav, Khemchand Rajendra Surana, Parag Ashok Pathade, Sunil Kashinath Mahajan

    Remogliflozin etabonate, a selective inhibitor of SGLT2, is prescribed for managing type 2 diabetes mellitus. To support quality control and routine testing, a dependable and efficient analytical technique is essential. The present study consists of a rapid, precise, and straightforward Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) method development for quantifying remogliflozin etabonate. An Inertsil ODS-3V column (150*4.6 mm, 5 µm) was used for separation. Optimization of the mobile phase was done from methanol: water (70:30, v/v) to acetonitrile: water (75:25, v/v), flow rate of 1.0 mL/min, and samples were analysed at 230 nm using a UV detector. ICH Q2(R1) was followed for validation of the method to assess various parameters like linearity, accuracy, precision, robustness, LOD, and LOQ. The assay demonstrated excellent linearity over 10–50 µg/mL (R² = 0.999), with a retention time of 2.55 min. Precision results showed %RSD values below 2%, while recovery studies confirmed accuracy within 98–102%. The calculated LOD and LOQ were 0.22 µg/mL and 0.68 µg/mL, respectively. The validated technique proved to be simple and robust, with adequate specificity, and can be effectively applied for routine analysis of remogliflozin etabonate in bulk as well as pharmaceuticals.


  • Open Access

    Insilico and Biological Evaluation of Anti-Inflammatory Activity of synthesized Benzimidazoles Derivatives

    by Khemchand R. Surana, Pallavi S. Jadhav, Harshada S. Shewale, Dipa B. Wagh, Sunil K. Mahajan, Jayesh V. Musale, Jubershaha S. Fakir, Yogesh P. Sharma

    We have developed a mild, easy, and highly efficient green catalyst for the synthesis of 2-substituted benzimidazole. In this study, Ace-dock and DockThore performed molecular docking of the designed benzimidazole molecules with the selected protein FAAH (PDB ID: 3LJ7). We assessed the drug's likeliness (Lipinski's rule of 5) and potential toxicity using the Protox-II software. We can confidently state that the synthesized molecules adhere to Lipinski's rule of five, given that the design molecules' properties are within acceptable limits. In comparison to the reference Ibuprofen, the proposed compounds exhibited favorable pharmacokinetic properties and achieved docking scores ranging from -10.88 to -27.31 (Acedock) and -6.045 to 9.122 (DockThore). We synthesized the benzimidazole derivatives 3a to 3g. Based on an in silico study, we synthesized the molecules, chose the best ones, and then tested their anti-inflammatory action in a lab setting. We employed the albumin denaturation assay test to determine the extent of heat-induced protein denaturation inhibition. Both of the synthesized compounds and the standard drug, diclofenac sodium, inhibit denaturation of proteins at concentrations between 10 and 50 ppm. At a dose of 10 ppm, compound 3f showed the highest level of inhibition, at 70%. Diclofenac sodium exhibited the highest suppression, measuring 97.20% at a concentration of 40 ppm. We could further investigate 3F to determine its anti-inflammatory characteristics.


  • Open Access

    Formulation and Evaluation of Antibacterial and Anti-Inflammatory Emulgel Containing Eugenia caryophyllus Buds Extract

    by Jubershaha S. Fakir, Chandrakant M. Ahire, Khemchand R. Surana, Abdul Kalam, Ayaz A. Ahamad, Madhuri D. Davanage, Sunil K. Mahajan

    Background: Eugenia caryophyllus is a valuable aromatic spice used in household cooking. Traditional healers frequently employ the plant, which is said to have therapeutic qualities, in herbal concoctions to treat a variety of illnesses and conditions. Objective: Eugenia caryophyllus clove buds have antibacterial, analgesic, and anti-inflammatory properties. The formulation of clove emulgel and its assessment using a variety of evaluation criteria were the main objectives of the current study. Clove emulgel was evaluated for its anti-inflammatory and anti-microbial properties. Materials and Procedures: We extracted and assessed the oils from Eugenia caryophyllus buds for phytochemical testing using solvents such as methanol, ethanol, petroleum ether, and N-hexane. We prepare emulgel and test it for spreadability, pH, and other organoleptic characteristics. We used egg albumin denaturation as a protein to measure the in vitro anti-inflammatory efficacy. We tested the antibacterial susceptibility using the agar-well diffusion method. Results: Alkaloids, saponins, tannins, steroids, carbohydrates, and glycosides were the phytochemical components found in clove bud extract. Physical factors such as color, consistency, and state—such as semi-solid, smooth, and brownish-gummy—are included in this category of evaluation parameters. The emulgel's pH was 5.35, its spreadability ranged from 1.6 to 2.5 cm, and no phase separation was noticed while the emulgel was stored. An in vitro anti-inflammatory test (spectroscopy method) and an antimicrobial test (zone of inhibition) were used to evaluate the anti-inflammatory activity of emulgel. Comparing clove oil emulgel to a typical medication, these evaluations found that it demonstrates strong anti-inflammatory and antibacterial resistance. Conclusion: In conclusion, Clove Buds Emulgel has demonstrated antibacterial activity against both gram-positive and gram-negative bacterial strains. Emulgel demonstrated the inhibitory response percentage in relation to the standard. This validates the roles that E. caryophyllus has been shown to play in protecting human health. This innovative emulgel mixture was applied to arthritis to lessen microbial infection and joint discomfort. In addition, more preclinical and clinical trials will be needed for this research in order to successfully commercialize the emulgel formulation for the treatment of inflammation and antimicrobial activity.


  • Open Access

    Insilico Drug Design, Synthesis and Evaluation of Anti-inflammatory Activity Pyrimidine Analogue

    by Sanket N. Aher, Sanjana N. Sonawane, Pawan R. Sonawane, Khemchand R. Surana, Sunil K. Mahajan, Dhananjay M. Patil, Pramod N. Katkade

    A class of pyrimidine-based molecules was designed for their in silico study, synthesis, and testing for their in vitro anti-inflammatory evaluation. The compounds were tested in an in silico study against anti-inflammatory proteins like FAAH (PDB ID: 4DO3) by using two different software programmes, Ace-dock and Arguslab, and showed promising signs of being a possible drug candidate. In silico toxicity prediction was also done on these compounds. The drug-likeness screening was done to satisfy the Lipinsky rule of five. In our recent investigation, we focused on environment-friendly approaches to synthesising pyrimidine derivatives in the presence of an ethanolic potassium hydroxide solution. The Claisen-Schmidt condensation of acetophenone and various substituted benzaldehydes produces pyrimidine. The pyrimidine derivatives 2a-p and 3a-c were synthesized. The synthesised molecules were screened on the basis of an in silico study, and the molecules were selected and subjected to a check for their in vitro anti-inflammatory activity. A test called the albumin denaturation assay was used to see how much heat-induced protein denaturation could be stopped. The compounds that were synthesised and the standard drug, diclofenac sodium, both stopped protein denaturation at levels ranging from 100 to 500 ppm. Maximum inhibition of 68.59% was observed at the concentration of 100 ppm of compound 2d. Diclofenac sodium showed the maximum inhibition, which was 80.58% at a concentration of 100 ppm. It is concluded that 2d has the potential for further investigation for anti-inflammatory activity.